Pharmexa has sold previously licensed patent rights to Bavarian Nordic

 | Source: Affitech A/S Affitech A/S 

Pharmexa has sold the previously licensed patent rights to Bavarian Nordic's
MVA-BN-HER2 vaccine for a single cash payment. This transaction will reduce
patent costs as well as improve Pharmexa's cash position. 


Hørsholm, February 23, 2009


Achim Kaufhold
Chief Executive Officer

Additional information: 

Claude Mikkelson, Senior Vice President, Finance and Investor Relations, tel
+45 4516 2525 or +45 4060 2558 
Achim Kaufhold, Chief Executive Officer, tel +45 4516 2525

Attachments

pharmexa press release 2009-3-uk.pdf
GlobeNewswire